One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Flashback Foreword: Nivolumab in Advanced Melanoma: Survival and Long-Term Safety.
Schwartz, Gary K. MD 1,2,,
doi : 10.1200/JCO.22.02333
Volume 41(5) pgs. 941-1158,e1-e20 February 10, 2023
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab.
Topalian, Suzanne L.; Sznol, Mario; McDermott, David F.; Kluger, Harriet M.; Carvajal, Richard D.; Sharfman, William H.; Brahmer, Julie R.; Lawrence, Donald P.; Atkins, Michael B.; Powderly, John D.; Leming, Philip D.; Lipson, Evan J.; Puzanov, Igor; Smith, David C.; Taube, Janis M.; Wigginton, Jon M.; Kollia, Georgia D.; Gupta, Ashok; Pardoll, Drew M.; Sosman, Jeffrey A.; Hodi, F. Stephen
doi : 10.1200/JCO.22.02272
Programmed cell death 1 (PD-1) is an inhibitory receptor expressed by activated T cells that downmodulates effector functions and limits the generation of immune memory. PD-1 blockade can mediate tumor regression in a substantial proportion of patients with melanoma, but it is not known whether this is associated with extended survival or maintenance of response after treatment is discontinued.
ASCO Living Guidelines: The Next Frontier.
Giri, Veda N. MD 1,,; Oliver, Thomas K. BA 2; Rumble, R. Bryan MSc 2; Friedberg, Jonathan W. MD 3,; Miller, Kathy D. MD 4,; Geisel, Rachel L. BS 2
doi : 10.1200/JCO.22.02344
Onco-Hypertension: Changing Paradigm of Treating Hypertension in Patients With Cancer.
Sahni, Gagan MD 1,
doi : 10.1200/JCO.22.01875
AB The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches.
Nonsurgical Options for Risk Reduction of Contralateral Breast Cancer in BRCA Mutation Carriers With Early-Stage Breast Cancer.
Evron, Ella MD 1; Ben-David, Merav A. MD 2; Kaidar-Person, Orit MD 3; Corn, Benjamin W. MD 4,,
doi : 10.1200/JCO.22.01609
Ensuring Employment After Cancer Diagnosis: Are Workable Solutions Obvious?.
Bradley, Cathy J. PhD, MPA 1,; Shih, Ya-Chen Tina PhD 2; Yabroff, K. Robin PhD 3,
doi : 10.1200/JCO.22.00929
A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update.
Makker, Vicky MD 1,2,,; Aghajanian, Carol MD 1,2,; Cohn, Allen L. MD 3,; Romeo, Margarita MD, PhD 4,; Bratos, Raquel MD 5; Brose, Marcia S. MD, PhD 6,; Messing, Mark MD 7; Dutta, Lea PharmD 8,; Dutcus, Corina E. MD 8,; Huang, Jie PhD 8,; Schmidt, Emmett V. MD, PhD 9,; Orlowski, Robert MD 9,; Taylor, Matthew H. MD 10,
doi : 10.1200/JCO.22.01021
AB Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available.
Blood Pressure Classification Using the 2017 ACC/AHA Guideline and Heart Failure in Patients With Cancer.
Kaneko, Hidehiro MD 1,2,,; Yano, Yuichiro MD 3,4; Lee, Hokyou MD 5,6; Lee, Hyeok-Hee MD 5,6; Okada, Akira MD 7; Suzuki, Yuta PhD 1,8; Itoh, Hidetaka MD 1; Matsuoka, Satoshi MD 1; Fujiu, Katsuhito MD 1,2; Michihata, Nobuaki MD 9; Jo, Taisuke MD 9,; Takeda, Norifumi MD 1; Morita, Hiroyuki MD 1; Nishiyama, Akira MD 10,; Node, Koichi MD 11; Kim, Hyeon Chang MD 5,6; Yasunaga, Hideo MD 12; Komuro, Issei MD 1,
doi : 10.1200/JCO.22.00083
Despite the growing recognition of the importance of hypertension in patients with cancer, little is known about whether high blood pressure (BP) among patients with cancer is associated with incident heart failure (HF) and other cardiovascular disease (CVD) events and what BP levels are linked to these events.
BRCA-CRisk: A Contralateral Breast Cancer Risk Prediction Model for BRCA Carriers.
Sun, Jie MD, PhD 1; Chu, Futao MD 2; Pan, Jiani MD 3,4; Zhang, Yaxin MD 1; Yao, Lu MD 1; Chen, Jiuan BS 1; Hu, Li MD, PhD 1; Zhang, Juan MD, PhD 1; Xu, Ye MD, PhD 1; Wang, Xiaojia MD 3; Cao, Wenming MD, PhD 3; Xie, Yuntao MD, PhD 1,2,
doi : 10.1200/JCO.22.00833
The absolute cumulative risk of contralateral breast cancer (CBC) for patients with BRCA1/2 variants is unknown. The purpose of this study was to develop a CBC risk prediction model for assessing CBC risk for BRCA1/2 carriers.
Financial Hardship in Adult Survivors of Childhood Cancer in the Era After Implementation of the Affordable Care Act: A Report From the Childhood Cancer Survivor Study.
Nathan, Paul C. MD, MSc 1,; Huang, I-Chan PhD 2; Chen, Yan MMath 3; Henderson, Tara O. MD 4,; Park, Elyse R. PhD 5,; Kirchhoff, Anne C. PhD 6,; Robison, Leslie L. PhD 2; Krull, Kevin PhD 2,; Leisenring, Wendy ScD 7,; Armstrong, Gregory T. MD 2,; Conti, Rena M. PhD 8; Yasui, Yutaka PhD 2; Yabroff, K. Robin PhD 9,
doi : 10.1200/JCO.22.00572
To estimate the prevalence of financial hardship among adult survivors of childhood cancer compared with siblings and identify sociodemographic, cancer diagnosis, and treatment correlates of hardship among survivors in the era after implementation of the Affordable Care Act.
Financial Burden in Blood or Marrow Transplantation Survivors During the COVID-19 Pandemic: A BMTSS Report.
Bhatia, Smita MD, MPH 1,2,,; Dai, Chen MS 1; Hageman, Lindsey MPH 1; Wu, Jessica MPH 1; Schlichting, Elizabeth MBA 1; Siler, Arianna BA 1; Funk, Erin BA 1; Hicks, Jessica BS 1; Lim, Shawn BS 1; Balas, Nora MSPH 1; Bosworth, Alysia BA 3; Te, Hok Sreng BA 4; Francisco, Liton BS 1; Bhatia, Ravi MD 5; Forman, Stephen J. MD 5,; Wong, F. Lennie PhD 3; Arora, Mukta MD, MS 4,; Armenian, Saro H. DO, MPH 3; Weisdorf, Daniel J. MD 4,; Landier, Wendy PhD 1,2,
doi : 10.1200/JCO.22.00461
The financial burden experienced by blood or marrow transplant (BMT) survivors during the COVID-19 pandemic remains unstudied. We evaluated the risk for high out-of-pocket medical costs and associated financial burden experienced by BMT survivors and a sibling comparison group during the COVID-19 pandemic.
Positron Emission Tomography-Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance).
LaCasce, Ann S. MD 1,,; Dockter, Travis MS 2; Ruppert, Amy S. PhD 3,; Kostakoglu, Lale MD 4,; Schoder, Heiko MD 5; Hsi, Eric MD 6,; Bogart, Jeffrey MD 7,; Cheson, Bruce MD 8,; Wagner-Johnston, Nina MD 9,; Abramson, Jeremy MD 10,; Blum, Kristie MD 11,; Leonard, John P. MD 12,; Bartlett, Nancy L. MD 9,
doi : 10.1200/JCO.22.00947
: Patients with bulky stage I/II classic Hodgkin lymphoma (cHL) are typically treated with chemotherapy followed by radiation. Late effects associated with radiotherapy include increased risk of second cancer and cardiovascular disease.
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.
Hillmen, Peter MBChB, PhD 1,; Eichhorst, Barbara MD 2,; Brown, Jennifer R. MD, PhD 3,; Lamanna, Nicole MD 4,; O'Brien, Susan M. MD 5,; Tam, Constantine S. MBBS, MD 6-9,; Qiu, Lugui MD, PhD 10; Kazmierczak, Maciej MD, PhD 11; Zhou, Keshu MD, PhD 12; Simkovic, Martin MD, PhD 13,14,; Mayer, Jiri MD 15,; Gillespie-Twardy, Amanda MD 16; Shadman, Mazyar MD, MPH 17,18,; Ferrajoli, Alessandra MD 19,; Ganly, Peter S. BMBCh, PhD 20; Weinkove, Robert MBBS, PhD 21,22,; Grosicki, Sebastian MD, PhD 23; Mital, Andrzej MD, PhD 24; Robak, Tadeusz MD, PhD 25,; Osterborg, Anders MD, PhD 26,27; Yimer, Habte A. MD 28,; Salmi, Tommi MD 29,; Ji, Meng MD 30,; Yecies, Jessica PhD 29,; Idoine, Adam PhD 29,; Wu, Kenneth PhD 29,; Huang, Jane MD 29,; Jurczak, Wojciech MD, PhD 31,
doi : 10.1200/JCO.22.00510
Zanubrutinib is a potent, irreversible next-generation Bruton tyrosine kinase (BTK) inhibitor designed to maximize BTK occupancy and minimize off-target kinase inhibition.
Health Benefits and Cost-Effectiveness of Children's Oncology Group Breast Cancer Screening Guidelines for Chest-Irradiated Hodgkin Lymphoma Survivors.
Wong, F. Lennie PhD 1,; Lee, Janie M. MD, MSc 2,; Leisenring, Wendy M. ScD 3,; Neglia, Joseph P. MD, MPH 4; Howell, Rebecca M. PhD 5,; Smith, Susan A. MPH 5; Oeffinger, Kevin C. MD 6; Moskowitz, Chaya S. PhD 7; Henderson, Tara O. MD, MPH 8,; Mertens, Ann PhD, MS 9; Nathan, Paul C. MD, MSc 10; Yasui, Yutaka PhD 11; Landier, Wendy PhD 12,; Armstrong, Gregory T. MD 11,; Robison, Leslie L. PhD 11; Bhatia, Smita MD, MPH 12,
doi : 10.1200/JCO.22.00574
To evaluate the outcomes and cost-effectiveness of the Children's Oncology Group Guideline recommendation for breast cancer (BC) screening using mammography (MAM) and breast magnetic resonance imaging (MRI) in female chest-irradiated childhood Hodgkin lymphoma (HL) survivors.
Racial and Ethnic Disparities in Cervical Cancer Incidence, Survival, and Mortality by Histologic Subtype.
Cohen, Camryn M. BS 1,; Wentzensen, Nicolas MD, PhD, MS 1; Castle, Philip E. PhD, MPH 1,2; Schiffman, Mark MD, MPH 1; Zuna, Rosemary MD 3; Arend, Rebecca C. MD 4,; Clarke, Megan A. PhD, MHS 1
doi : 10.1200/JCO.22.01424
We conducted an integrated population-based analysis of histologic subtype-specific cervical cancer incidence, survival, and incidence-based mortality by race and ethnicity, with correction for hysterectomy prevalence.
Smartphone Psychotherapy Reduces Fear of Cancer Recurrence Among Breast Cancer Survivors: A Fully Decentralized Randomized Controlled Clinical Trial (J-SUPPORT 1703 Study).
Akechi, Tatsuo MD, PhD 1,2,,; Yamaguchi, Takuhiro PhD 3,; Uchida, Megumi MD, PhD 1,2; Imai, Fuminobu MD, PhD 1,2; Momino, Kanae RN, PhD 4; Katsuki, Fujika RN, PhD 5; Sakurai, Naomi BA, PE 6; Miyaji, Tempei MSc 7,; Mashiko, Tomoe RN, PhD 8,9; Horikoshi, Masaru PhD 10; Furukawa, Toshi A. MD, PhD 11,; Yoshimura, Akiyo MD, PhD 12,; Ohno, Shinji MD, PhD 13,; Uehiro, Natsue MD, PhD 13; Higaki, Kenji MD, PhD 14; Hasegawa, Yoshie MD, PhD 15; Akahane, Kazuhisa MD, PhD 16; Uchitomi, Yosuke MD, PhD 8,9; Iwata, Hiroji MD, PhD 12,
doi : 10.1200/JCO.22.00699
Fear of cancer recurrence (FCR) is a common distressing condition. We investigated the efficacy of smartphone problem-solving therapy and behavioral activation applications in breast cancer survivors.
Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702.
Lee, Seohyuk BSc 1; Ma, Chao MS 2; Shi, Qian PhD 3,; Kumar, Pankaj MD 4; Couture, Felix MD 5,; Kuebler, Philip MD 6,; Krishnamurthi, Smitha MD 7,; Lewis, DeQuincy MD 8,; Tan, Benjamin MD 9,; Goldberg, Richard M. MD 10,; Venook, Alan MD 11,; Blanke, Charles MD 12; O'Reilly, Eileen M. MD 13,; Shields, Anthony F. MD 14,; Meyerhardt, Jeffrey A. MD, MPH 2,,
doi : 10.1200/JCO.22.01637
We sought to evaluate the independent and interactive associations of planned treatment duration, celecoxib use, physical activity, body mass index (BMI), diabetes mellitus, and vitamin B6 with oxaliplatin-induced peripheral neuropathy (OIPN) among patients with stage III colon cancer enrolled in a clinical trial
CanRisk-Prostate: A Comprehensive, Externally Validated Risk Model for the Prediction of Future Prostate Cancer.
Nyberg, Tommy PhD 1,2,; Brook, Mark N. PhD 3; Ficorella, Lorenzo PhD 1; Lee, Andrew PhD 1,; Dennis, Joe MSc 1; Yang, Xin PhD 1; Wilcox, Naomi MSc 1; Dadaev, Tokhir MSc 3; Govindasami, Koveela MSc 3; Lush, Michael PhD 1; Leslie, Goska MEng 1; Lophatananon, Artitaya PhD 4; Muir, Kenneth PhD 4; Bancroft, Elizabeth RN 3,5; Easton, Douglas F. PhD 1,; Tischkowitz, Marc PhD 6; Kote-Jarai, Zsofia PhD 3; Eeles, Rosalind PhD 3,5,; Antoniou, Antonis C. PhD 1,
doi : 10.1200/JCO.22.01453
Prostate cancer (PCa) is highly heritable. No validated PCa risk model currently exists. We therefore sought to develop a genetic risk model that can provide personalized predicted PCa risks on the basis of known moderate- to high-risk pathogenic variants, low-risk common genetic variants, and explicit cancer family history, and to externally validate the model in an independent prospective cohort.
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer.
Camidge, D. Ross MD, PhD 1,,; Barlesi, Fabrice MD, PhD 2,3,; Goldman, Jonathan W. MD 4,; Morgensztern, Daniel MD 5,; Heist, Rebecca MD, MPH 6,; Vokes, Everett MD 7,; Spira, Alex MD, PhD 8,; Angevin, Eric MD, PhD 9,; Su, Wu-Chou MD 10,; Hong, David S. MD 11; Strickler, John H. MD 12,; Motwani, Monica PhD 13,; Dunbar, Martin PhD 13,; Parikh, Apurvasena PhD 14,; Noon, Elysa PhD 13,; Blot, Vincent PhD 13,; Wu, Jun MD 13,; Kelly, Karen MD 15,
doi : 10.1200/JCO.22.00739
Overexpression of c-Met protein and epidermal growth factor receptor (EGFR) mutations can co-occur in non-small-cell lung cancer (NSCLC), providing strong rationale for dual targeting. Telisotuzumab vedotin (Teliso-V), a first-in-class antibody-drug conjugate targeting c-Met, has shown a tolerable safety profile and antitumor activity as monotherapy.
Rare Germline ATM Variants Influence the Development of Chronic Lymphocytic Leukemia.
Lampson, Benjamin L. MD, PhD 1; Gupta, Aditi PhD 1,; Tyekucheva, Svitlana PhD 2; Mashima, Kiyomi MD, PhD 1; Petrackova, Anna PhD 3; Wang, Zixu BS 2; Wojciechowska, Natalia BS 4,5; Shaughnessy, Conner J. BS 1,; Baker, Peter O. BS 1; Fernandes, Stacey M. BS 1; Shupe, Samantha BS 1; Machado, John-Hanson BS 1; Fardoun, Rayan BS 1; Kim, Annette S. MD, PhD 4,; Brown, Jennifer R. MD, PhD 1,,
doi : 10.1200/JCO.22.00269
Germline missense variants of unknown significance in cancer-related genes are increasingly being identified with the expanding use of next-generation sequencing.
Exploring the Next Frontier in Non-Small-Cell Lung Cancer With High MET and Mutated Epidermal Growth Factor Receptor.
Sattler, Martin PhD 1,2; Salgia, Ravi MD, PhD 3,,
doi : 10.1200/JCO.22.02086
Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline.
Yilmaz, Emrullah MD, PhD 1,; Ismaila, Nofisat MD 2,; Bauman, Julie E. MPH, MD 3,; Dabney, Raetasha MD 4,; Gan, Gregory MD, PhD 5,; Jordan, Richard DDS, PhD 6,; Kaufman, Marnie 7; Kirtane, Kedar MD 8,; McBride, Sean Matthew MD, MPH 9,; Old, Matthew O. MD 10,; Rooper, Lisa MD 11; Saba, Nabil F. MD 12,; Sheth, Siddharth DO, MPH 13,; Subramaniam, Rathan M. MD, PhD, MPH, MBA 14,15; Wise-Draper, Trisha Michel MD, PhD 16,; Wong, Deborah MD, PhD 17,; Mell, Loren K. MD 18,
doi : 10.1200/JCO.22.02328
To provide evidence-based recommendations for practicing physicians and other health care providers on immunotherapy and biomarker testing for head and neck cancers.
Winning the Battle But Losing the War: Single-Cancer Screening Trials.
Raoof, Sana MD, PhD
doi : 10.1200/JCO.22.01668
Reply to S. Raoof.
Dbouk, Mohamad MD; Katona, Bryson W. MD; Brand, Randall E. MD; Chak, Amitabh MD; Syngal, Sapna MD; Farrell, James J. MD; Kastrinos, Fay MD; Stoffel, Elena M. MD; Canto, Marcia Irene MD; Goggins, Michael MB, MD
doi : 10.1200/JCO.22.01915
The Methodology of the ASCO Living Guidelines Should Be Improved and Refined.
Luo, Xufei PhD Candidate; Lv, Meng PhD Candidate; Chen, Yaolong MD, PhD
doi : 10.1200/JCO.22.01871
Reply to X. Luo et al.
Giri, Veda N. MD; Oliver, Thomas K. BA; Rumble, R. Bryan MSc; Geisel, Rachel L. BS
doi : 10.1200/JCO.22.02126
Neurological Manifestations as a Harbinger of Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.
Rossi, Simone MD; Cani, Ilaria MD; Raschi, Emanuel MD, PhD; Comito, Francesca MD, PhD; Rinaldi, Rita MD; Ardizzoni, Andrea MD; Guarino, Maria MD; Gelsomino, Francesco MD
doi : 10.1200/JCO.22.01602
Underreporting of Major Cardiac Adverse Events With Immune Checkpoint Inhibitors in Clinical Trials: Importance of Postmarketing Pharmacovigilance Surveys.
Palassin, Pascale PharmD, PhD; Faillie, Jean-Luc MD, PhD; Coustal, Cyrille MD; Quantin, Xavier MD, PhD; Topart, Delphine MD; Roubille, Francois MD, PhD; Maria, Alexandre T.J. MD, PhD
doi : 10.1200/JCO.22.01603
Reply to S. Rossi et al and P. Palassin et al.
Naqash, Abdul Rafeh MD; Johnson, Douglas B. MD; Moslehi, Javid J. MD; Sharon, Elad MD, MPH
doi : 10.1200/JCO.22.01928
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.2
Owen, Dwight H. MD, MS 1,; Singh, Navneet MD, DM 2; Ismaila, Nofisat MD, MSc 3,; Blanchard, Elizabeth MD 4,; Celano, Paul MD 5; Florez, Narjust MD 6,; Jain, Dharamvir MD 7; Leighl, Natasha B. MD 8,; Mamdani, Hirva MD 9,; Masters, Gregory MD 10; Moffitt, Pamela R. 11; Naidoo, Jarushka MD 12,; Phillips, Tanyanika MD 13,; Riely, Gregory J. MD, PhD 14,; Robinson, Andrew G. MD 15,; Schenk, Erin MD 16,; Schneider, Bryan J. MD 17,; Sequist, Lecia MD 18,; Spigel, David R. MD 19,; Jaiyesimi, Ishmael A. MD, MS 20
doi : 10.1200/JCO.22.02121
AB Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual.
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2
Owen, Dwight H. MD, MS 1,; Singh, Navneet MD, DM 2; Ismaila, Nofisat MD, MSc 3,; Blanchard, Elizabeth MD 4,; Celano, Paul MD 5; Florez, Narjust MD 6,; Jain, Dharamvir MD 7; Leighl, Natasha B. MD 8,; Mamdani, Hirva MD 9,; Masters, Gregory MD 10; Moffitt, Pamela R. 11; Naidoo, Jarushka MD 12,; Phillips, Tanyanika MD 13; Riely, Gregory J. MD, PhD 14,; Robinson, Andrew G. MD 15,; Schenk, Erin MD 16,; Schneider, Bryan J. MD 17,; Sequist, Lecia MD 18,; Spigel, David R. MD 19,; Jaiyesimi, Ishmael A. MD, MS 20
doi : 10.1200/JCO.22.02124
AB Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual. ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines.
